Worldwide orphan drug sales forecast to total $178bn in 2020

EvaluatePharma has just released their Orphan Drug Report 2015. This free report contains tons of great information on the current state of the market. A few highlights below:

- Median cost per patient differential is 13.8 times higher for orphan drugs compared to non-orphan

- Phase III orphan drug development costs half that of non-orphan but Phase III drug development

- Worldwide orphan drug sales forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the overall prescription market growth

To download a full copy of this free report, please click on the following link: http://www.evaluategroup.com/public/reports/EvaluatePharma-Orphan-Drug-Report-2015.aspx#anchor

#patagonia #orphandrug #evaluatepharma #pharmaceuticals #patient #prescriptions #biotech #raredisease